A key tariff exemption considers a drug's origin to be where its Active Pharmaceutical Ingredient (API) was made. This allows companies to manufacture an API in the US, export it for final formulation, and then re-import the finished product tariff-free, offering a significant supply chain strategy to bypass import taxes.

Mark Cuban reveals the primary barrier to making generic drugs in the US isn't production cost, which can be cheaper than overseas, but the prohibitive FDA application fees costing hundreds of thousands per drug.

Amid debates about high drug prices, it's often overlooked that the existing patent cliff model is highly effective. 90% of all prescriptions in the U.S. are for low-cost generic drugs, demonstrating the system's ability to reduce prices at scale once patent exclusivity ends.

Despite claims of "American-made" peptides, the raw Active Pharmaceutical Ingredient (API) for compounds sold by compounding pharmacies and research sites is almost exclusively synthesized in China. Finishing, packaging, and quality control may occur domestically, but the core ingredient is imported.

A speaker directly challenges the common narrative that China's dominance has destroyed India's Active Pharmaceutical Ingredient (API) sector. This suggests Indian API manufacturing remains a competitive and viable industry, despite widespread reports to the contrary.

Contrary to widespread belief, generic drugs are not always identical to brand-name versions. Experts estimate a 13% failure rate, meaning they may lack potency, contain contaminants like arsenic, or have faulty delivery mechanisms, posing significant safety risks.

Contrary to the popular narrative, China doesn't dominate the final API market against India. Instead, China's strategy is to supply low-cost chemical intermediates. Indian firms then perform the final, more complex and profitable conversion steps to create the finished Active Pharmaceutical Ingredient (API).

India produces 60% of the world's drugs by volume but captures only 2-5% of the revenue. This disparity exists because it dominates the post-patent generic market, where prices can fall by over 95%, while innovator companies capture the high-margin monopoly period.

In a market with many identical branded generics, doctors' prescribing decisions are driven by personal relationships, not product features. Pharma giants employ vast sales forces (10k-17k reps) whose primary job is to visit doctors, build rapport, and convince them to prescribe their version of a drug.